Transforming Diabetes Care: Pharmacist-Led Education and Its Impact on Patient Knowledge, Self-Management, and Health Outcomes

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorShifa International Hospital

About this trial

This interventional study is to evaluate the impact of pharmacist-led education on diabetic patients' knowledge, self-management, and overall health outcomes. Participants in this study will attend pharmacist-led educational sessions designed to improve their understanding of diabetes and self-care practices. Researchers will assess changes in patients' knowledge, self-management behaviors, and clinical health markers before and after the intervention. The study will compare pre- and post-intervention results to determine the effectiveness of pharmacist-led education in transforming diabetes care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

We will include all confirmed diabetic patients who visit the SIH endocrinology OPD Clinic during the study duration.

Both male and female patients visiting the Endocrinology Unit of the hospital will be eligible.

Patients with HbA1c levels greater than 8% will be included.

Both follow-up and newly diagnosed patients will be considered.

Disqualifiers

We will exclude patients with gestational diabetes mellitus (GDM).

Patients with central obesity will not be included in the study.

Type 1 diabetes mellitus (DM) patients under the age of 20 will be excluded.

Patients with inadequate medical history will be excluded from participation.

Trial design

Design model

Single group

Treatments tested in this trial

  • Pharmacist led Education

    Behavioral

    Pharmacist-led education for diabetic patients focuses on enhancing their understanding of the disease, improving self-management skills, and promoting better health outcomes. The education covers key aspects of diabetes, such as the importance of blood sugar control, the role of diet and exercise, and how to monitor blood glucose levels. Patients are also taught effective self-management strategies, including how to make healthy food choices, incorporate physical activity into daily routines, and manage potential complications. By providing tailored education, pharmacists aim to empower patients to take an active role in their care, which can lead to improved disease management, better glycemic control, and reduced risk of complications.

Treatment groups

385 Participants
are divided into 1 treatment group
Group A: Interventional GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Diabetes Knowledge Score(DKQ-24)

Patient's diabetes knowledge will be assessed using the Diabetes Knowledge Questionnaire (DKQ). The DKQ is a tool used to evaluate a patient's understanding of diabetes, including aspects such as blood sugar control, diet, exercise, and medication management. It consists of close-ended questions, with scores ranging from 0 to 100, where a higher score indicates a better level of knowledge regarding diabetes management.

Time frame
3 months
2

Diabetes Management Self-Efficacy Score (DMSQ-16)

Patient's diabetes self-management will be assessed using the Diabetes Self-Management Questionnaire (DMSQ). The DMSQ is a tool used to evaluate a patient's ability to manage their diabetes through self-care practices, including diet, physical activity, blood sugar monitoring, and medication adherence. It consists of close-ended questions, with scores ranging from 0 to 100, where a higher score reflects better self-management behaviors in managing diabetes.

Time frame
3 months
3

HbA1C Levels (%)

Patient's health outcomes will be assessed using HbA1c levels. HbA1c (glycated hemoglobin) is a blood test used to measure a patient's average blood sugar level over the past 3 months. It is a key indicator of diabetes management and glycemic control. The HbA1c level is reported as a percentage, with lower percentages indicating better control of blood sugar. A target HbA1c level of less than 7% is typically recommended for most diabetic patients. The score can range from high percentages (indicating poor control) to lower percentages (indicating better glycemic control).

Time frame
3 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: